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AbstrAct:
VEGF is believed to be a master regulator in both developmental and 
pathological angiogenesis. The role of PDGF-C in angiogenesis, however, is only 
at the beginning of being revealed. We and others have shown that PDGF-C is a 
critical player in pathological angiogenesis because of its pleiotropic effects 
on multiple cellular targets. The angiogenic pathways induced by PDGF-C are, 
to a large extent, VEGF-independent. These pathways may include, but not 
limited to, the direct effect of PDGF-C on vascular cells, the effect of PDGF-C on 
tissue  stroma  fibroblasts,  and  its  effect  on  macrophages.  Taken  together,  the 
pleiotropic, versatile and VEGF-independent angiogenic nature of PDGF-C has 
placed it among the most important target genes for antiangiogenic therapy.
Abbreviations used:  Platelet-derived growth factor-C, PDGF-C; vascular endothelial growth factor, VEGF; pericyte, PC; smooth 
muscle cell, SMC; endothelial cell, EC; platelet-derived growth factor receptor, PDGFR; choroidal neovascularization, CNV; vas-
cular endothelial growth factor receptor, VEGFR; retinal pigment epithelial cell, RPE; extracellular matrix, ECM; matrix metallopro-
teinase, MMP
INtrODUctION
Since its discovery ten years ago as the third 
member of the platelet-derived growth factor (PDGF) 
family [1, 2], PDGF-C has been shown to play critical 
roles in many biological processes. Indeed, this is 
consistent with its general expression profile in most of 
the tissues and cell types investigated [1, 3]. PDGF-C 
is produced as a latent protein and requires proteolytic 
processing for receptor binding and activation [4]. Once 
activated, PDGF-C binds to the PDGFR-a homodimer 
and the PDGFR-a/β heterodimer [1,  3,  5-7].  PDGF-C 
is critically required for embryonic development, 
since  PDGF-C  deficient  mice  die  postnatally  due  to 
developmental defects when the mice are bred on a 129 
background [8]. We have recently shown that PDGF-C 
is a critical survival factor for different types of neurons 
[9], although it is recently reported that PDGF-C induced 
blood-brain barrier permeability during ischemic stroke 
[10, 11]. Moreover, the role of PDGF-C in tumor growth 
has been shown by several groups. PDGF-C promotes 
tumor growth via several mechanisms. First, PDGF-C 
is a transforming factor [12, 13]. Second, PDGF-C is a 
survival and mitogenic factor for tumor cells [14]. Third, 
PDGF-C is a mitogenic and chemoattractant factor for 
cancer-associated fibroblasts [15, 16]. Fourth, PDGF-C 
promotes  tumor  angiogenesis  [16,  17].  Considerable 
amount of research interests have been focused on the 
angiogenic activity of PDGF-C. Independent studies from 
different laboratories have shown that PDGF-C is a potent 
angiogenic factor in different model systems [5, 6, 16, 18, 
19]. However, it remains less discussed to what extent 
the angiogenic activity of PDGF-C is VEGF-independent 
or -dependent. In this perspective, we mainly discuss 
the angiogenic properties of PDGF-C in relation to the 
VEGF-independent angiogenic pathways induced by it, 
and the cellular components involved in these pathways.
PDGF-c is angiogenic in different models
PDGF-C is abundantly expressed in most of the 
highly angiogenic tissues, such as the placenta, ovary 
and embryo tissues [1, 3, 20]. Indeed, the angiogenic 
activity of PDGF-C occurs in many different organs and Oncotarget 2010; 1: 309-314 310 www.impactjournals.com/oncotarget
tissues. Infusion of PDGF-C protein alone increased the 
revascularization of ischemic mouse hearts, and induced 
angiogenesis in mouse ischemic hind limb [6]. In addition, 
the angiogenic activity of PDGF-C is comparable to that 
of VEGF in different model systems, such as in the aortic 
ring assay, chorioallantoic membrane assay and cornea 
pocket  assay  [3,  5].  The  potent  angiogenic  activity  of 
PDGF-C is linked to its effects on endothelial progenitor 
cells, bone marrow cells and mature vascular cells by 
promoting their recruitment, proliferation, differentiation 
and migration respectively [6, 7]. In the eye, PDGF-C 
also plays critical roles in choroidal, retinal and cornea 
neovascularization via its effects on multiple cellular 
targets, such as the vascular mural and endothelial cells, 
macrophages, choroidal fibroblasts, and retinal pigment 
epithelial (RPE) cells [5, 19]. 
The critical role of PDGF-C in tumor angiogenesis 
has been documented in different types of tumors [13, 
16, 17]. It is particularly important to note that in tumors 
expressing a high level of PDGF-C, tumor blood vessels 
developed  efficiently  even  when  VEGF  was  inhibited 
[16]. This demonstrated that PDGF-C does not require 
VEGF  activity  to  fulfill  its  angiogenic  function.  A 
combination therapy using both anti-PDGF-C and anti-
VEGF antibodies was more effective in inhibiting tumor 
angiogenesis than using anti-VEGF treatment alone 
[16].  Furthermore,  it  is  noteworthy  that  in  the  PDGF-
C-overexpressing tumors, the permeability of the tumor 
blood  vessels  was  decreased  [17],  in  contrast  to  the 
VEGF-induced blood vessels, which are often leaky. The 
fact that PDGF-C-induced blood vessels are functionally 
different from the ones induced by VEGF supports that 
PDGF-C uses different mechanisms than VEGF to build 
blood vessels.
broad range of cellular targets of PDGF-c
One important functional characteristic of PDGF-C 
is that it has a considerably broad range of cellular 
targets (Table 1). We have shown that PDGF-C promotes 
the proliferation, survival and migration of vascular 
pericytes, endothelial cells and fibroblasts [19]. Several 
groups have shown that PDGF-C has direct effects on 
macrophages. PDGF-C regulates gene expression in 
macrophages [19], and promotes their migration [21] 
and proliferation [22]. Moreover, PDGF-C induces 
proliferation and migration of retinal pigment epithelial 
cells [23]. PDGF-C also promotes the proliferation, 
survival and migration of vascular endothelial cells, 
smooth  muscle  cells  (SMC)  and  their  progenitors  [6, 
16]. In tumors, PDGF-C plays a critical role in recruiting 
fibroblasts  associated  with  tumor  drug  resistance  [15, 
16,  24]. Vascular  cells  are  the  most  important  cellular 
components in pathological angiogenesis. In addition, 
other  cell  types,  such  as  fibroblasts,  macrophages  and 
retinal pigment epithelial cells also play critical roles in 
different  types  of  pathological  neovascularization  [25, 
26]. It is noteworthy that pericytes, smooth muscle cells, 
fibroblasts, macrophages, retinal pigment epithelial cells, 
mesangial cells [27] and hepatic stellate cells [28] are not 
typical cellular targets of VEGF, which mainly affects 
vascular endothelial cells. Thus, at cellular level, the 
angiogenic pathways induced by PDGF-C are unique and 
different from those induced by VEGF. 
VEGF-independent angiogenic pathways induced 
by PDGF-c
Much insight into the VEGF-independent 
angiogenic pathways induced by PDGF-C has derived 
from studies on tumor angiogenesis. For example, in 
tumors overexpressing PDGF-C, treatment with an anti-
VEGFR-2 antibody, which blocks the VEGF pathway, 
had no effect on tumor angiogenesis, while it decreased 
blood vessel density in the control tumors without 
PDGF-C overexpression, demonstrating that the PDGF-
C-induced angiogenesis was not mediated by the VEGF 
pathway [17]. Indeed, this notion was further supported 
by  the  findings  that  in  VEGF-deficient  fibrosarcomas, 
tumor angiogenesis still developed without VEGF, and 
the PDGFR-α-mediated recruitment of stromal fibroblasts 
was believed to be responsible for the persistent tumor 
cell types references
Vascular endothelial cell [18], [6] & [16]
Vascular smooth muscle cell [18] & [3]
Vascular pericyte [18] & [3]
Fibroblast [18], [3], [15] & [16]
Macrophage [21]
Retinal pigment epithelium [23]
Neuron [9]
Vascular progenitor cell [6]
Tumor cell [12], [35] & [14]
Glomerular endothelial cell [22]
Mesangial cell [27]
Hepatic stellate cell [28]
table 1. Cellular targets of PDGF-COncotarget 2010; 1: 309-314 311 www.impactjournals.com/oncotarget
angiogenesis [29], further affirming a VEGF-independent 
tumor angiogenesis induced by PDGF-C. Moreover, these 
observations were corroborated by the findings from yet 
another study showing that in certain types of tumors 
that are resistant to anti-VEGF therapy, PDGF-C was 
responsible for mediating the VEGF-independent tumor 
angiogenesis by modulating the angiogenic properties 
of  tumor-associated  fibroblasts  [16].  In  addition,  it  is 
recently reported that in the kidney, PDGF-C induced 
proliferation of glomerular endothelial cells in a VEGF-
independent manner [22], indicating that the VEGF-
independent effect of PDGF-C is likely a general event. 
Indeed, more evidence of the VEGF-independent 
angiogenic pathways induced by PDGF-C comes from 
studies on pathological ocular angiogenesis, such as 
choroidal and retinal neovascularization [19]. In both a 
laser-induced choroidal neovascularization (CNV) model 
and an ischemia-induced retinal angiogenesis model, the 
expression level of PDGF-C increased markedly. In these 
models, PDGF-C inhibition affected not only vascular 
mural and endothelial cells, but also macrophages, 
choroidal fibroblasts and retinal pigment epithelial cells, 
which are not prototypical cellular targets of VEGF. At 
gene regulation level, PDGF-C significantly upregulated 
the expression of PDGF-B and PDGF receptors in 
macrophages and retinal pigment epithelial cells, and 
PDGF-C inhibition downregulated their expression [19]. 
PDGF-B is known to be one of the most potent stimuli 
of  pathological  angiogenesis  [30-34].  These  findings 
indicate that PDGF-C may be functionally related to the 
PDGF-B-induced angiogenic pathways.
taken together, accumulating data have shown 
that PDGF-c can induce VEGF-independent 
angiogenesis via at least three interrelated 
pathways:
(1) The vascular cell pathway: PDGF-C has direct 
effects on all three types of vascular cells, endothelial 
cells, pericytes and smooth muscle cells, by promoting 
their proliferation, survival and migration. Vascular 
pericytes and smooth muscle cells are classic cellular 
targets of the PDGFs [35]. In addition, certain types of 
vascular endothelial cells express the PDGF receptors 
[6, 36, 37] and respond to PDGF-C stimulation directly. 
PDGF-C thus can induce new blood vessel formation by 
increasing the number and availability of all three types of 
vascular cells (Fig. 1). 
(2) The tissue stroma pathway: Tissue stroma 
consists of blood vessels, extracellular matrix (ECM), 
mesenchymal cells, inflammatory cells, nerves, lymphatic 
vessels, etc. These components form a scaffold to support 
and promote new blood vessels to grow. Fibroblasts 
are the major component of mesenchymal cells and are 
one of the major sources of angiogenic growth factors, 
Figure 1: Effect of PDGF-c on three types of 
vascular cells. PDGF-C promotes the proliferation, survival 
and migration of all three types of vascular cells: endothelial cells 
(EC), pericytes and smooth muscle cells (SMC). Vascular pericytes 
and smooth muscle cells are known to be classic cellular targets 
of the PDGFs. In addition, certain types of vascular endothelial 
cells express the PDGF receptors and respond to PDGF-C directly. 
PDGF-C thus can induce angiogenesis by increasing the number 
and availability of all the three types of vascular cells. 
Figure 2: Effect of PDGF-C on fibroblasts. Fibroblasts 
are the principal component of mesenchymal cells and are a major 
source of host-derived angiogenic growth factors (GF), extracellular 
matrix (ECM), and ECM-degrading proteases, such as the matrix 
metalloproteinases (MMP). Under pathological conditions, the 
number of fibroblasts is increased due to the upregulated expression 
of chemotactant and mitogenic factors. PDGF-C is one of the most 
potent stimuli of fibroblast proliferation, migration and recruitment. 
Part of the angiogenic activity of PDGF-C is therefore exerted via 
its effect on fibroblasts. Oncotarget 2010; 1: 309-314 312 www.impactjournals.com/oncotarget
extracellular matrix, and ECM-degrading proteases such 
as the matrix metalloproteinases (MMPs). Fibroblasts can 
also regulate inflammation and epithelial differentiation. 
There  are  a  minimal  number  of  fibroblasts  in  normal 
stroma in most organs. However, under pathological 
conditions,  the  number  of  fibroblasts  increases  due 
to the upregulated expression of chemotactant and 
mitogenic factors. Because of their critical contributions 
to  pathological  angiogenesis,  fibroblasts  may  represent 
an important cellular target in antiangiogenic therapy 
[38]. PDGF-C has been shown to be one of the most 
potent stimuli for fibroblast proliferation, migration and 
recruitment [1, 3, 39]. A significant part of the angiogenic 
activity of PDGF-C is therefore exerted via its effect on 
fibroblasts (Fig. 2). 
(3)  The  inflammatory  cell  pathway:  It  is  known 
that  different  types  of  inflammatory  cells,  such  as 
macrophages, monocytes and neutrophils, play critical 
roles in the VEGF-independent pathological angiogenesis 
by producing a broad array of angiogenic growth factors 
and cytokines, generating conduits for new blood vessels 
through proteolytic mechanisms, and promoting the 
remodeling of arterioles into arteries [40, 41]. Particularly, 
macrophages are known to play a key role in promoting 
pathological angiogenesis in the retina and choroid in the 
eye [42]. Macrophages are required for the angiogenic 
switch of quiescent blood vessels in pathological 
conditions, and accumulation of macrophages accelerates 
this process [43]. Several groups have reported that 
PDGF-C is a potent regulator of macrophage migration, 
proliferation and gene expression [19, 21, 22, 44]. 
PDGF-C therefore can promote angiogenesis via its direct 
effect on macrophages (Fig. 3).
After  being  intensively  studied  for  about  two 
decades, VEGF has been commonly viewed as a master 
angiogenic factor in both developmental and pathological 
angiogenesis  [45,  46].  The  importance  of  PDGF-C  in 
neovessel formation, however, is only at the beginning of 
being realized. The function of PDGF-C in developmental 
angiogenesis still needs to be explored [8]. The role of 
PDGF-C in pathological angiogenesis, by contrast, 
has been better investigated [5, 6, 16, 18, 19]. In many 
models, the angiogenic effect of PDGF-C was as potent as 
that of VEGF, such as in the cornea [5], ischemic heart and 
limb [6]. Moreover, in pathological ocular angiogenesis, 
PDGF-C inhibition suppressed neovascularization to a 
similar degree as VEGF inhibition [19]. Thus, at least 
under certain pathological conditions, PDGF-C is as 
potent as VEGF in inducing angiogenesis, and is therefore 
as critical as VEGF to be inhibited when the growth of 
new blood vessels is harmful.
cONclUsION
We and other groups have provided ample evidence 
showing that PDGF-C is a critical regulator of pathological 
angiogenesis. The cellular targets of PDGF-C are 
considerably broad. The angiogenic pathways induced by 
PDGF-C are, to a large extent, VEGF-independent. These 
pathways may include, but not limited to: (1) direct effect 
of PDGF-C on different types of vascular cells, (2) effect 
of PDGF-C on tissue stroma formation, particularly, on 
fibroblast  recruitment,  proliferation  and  migration,  (3) 
effect of PDGF-C on inflammatory cells, especially, on 
macrophages. The pleiotropic, versatile and VEGF-
independent angiogenic nature of PDGF-C has placed it 
among the most critical target genes for antiangiogenic 
therapy.  Anti-PDGF-C  treatment  may  prove  to  be 
therapeutically valuable in treating neovascular diseases. 
Combination therapy aimed at inhibiting VEGF and 
PDGF-C simultaneously might provide better efficacy in 
inhibiting undesired blood vessel growth.
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Figure 3: Effect of PDGF-c on macrophages. 
Macrophages play critical roles in VEGF-independent pathological 
angiogenesis by producing a broad array of angiogenic growth 
factors (GF), cytokines and proteolytic proteinases, such as the 
matrix metalloproteinases (MMP). Macrophages are required for 
the angiogenic switch of blood vessels in pathological conditions, 
and accumulation of macrophages accelerates pathological 
angiogenesis. Several groups have reported that PDGF-C regulates 
macrophage migration, proliferation and gene expression. PDGF-C 
therefore can promote angiogenesis via its effect on macrophages.  Oncotarget 2010; 1: 309-314 313 www.impactjournals.com/oncotarget
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